Potential blockbuster drugs to watch in 2025
By European Pharmaceutical Review
AstraZeneca’s PARP inhibitor newly recommended by NICE
By Catherine Eckford (European Pharmaceutical Review)
ePI rollout backed in new paper by pharmaceutical bodies
By European Pharmaceutical Review
FDA issues first recommendations on AI for drug development
By Catherine Eckford (European Pharmaceutical Review)
Hydrogel encapsulation: unlocking the potential of cell therapies for targeted…
By Francis Karanu (Likarda), Stephen Harrington (Likarda)
The year ahead for RNA therapeutic development and manufacturing
By Dr Kate Broderick (Maravai Life Sciences and TriLink Biotechnologies)